Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-417-0 | CAS number: 8017-16-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Short summary of primary study.
Data source
Reference
- Reference Type:
- publication
- Title:
- Toxicological Characteristics of Phosphoric Acid and Some of its Chromium Salts Used as Binding Agents in the Production of Refractory Materials
- Author:
- Sigova N.V.
- Year:
- 1 983
- Bibliographic source:
- Gig. Truda prof. Patol.Tsv.cher. Metallurg.M, 65. Cited in : Bibra toxicology/advice and consulting. 1993. Toxicity Profile: Phosphoric acid and common inorganic phosphates
Materials and methods
- Principles of method if other than guideline:
- Chronic inhalation of hydro-aerosol of phopshoric acid in a concentration of 10.6 mg/m3 per P2O5.
- GLP compliance:
- no
- Limit test:
- yes
Test material
- Reference substance name:
- Orthophosphoric acid
- EC Number:
- 231-633-2
- EC Name:
- Orthophosphoric acid
- Cas Number:
- 7664-38-2
- Molecular formula:
- H3O4P
- IUPAC Name:
- phosphoric acid
- Details on test material:
- - Name of test material (as cited in study report): phosphoric acid
- Other: administered as hydro-aerosol of phosphoric acid expressed as per P2O5
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- not specified
- Vehicle:
- not specified
- Remarks on MMAD:
- MMAD / GSD: No data
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- No data
- Frequency of treatment:
- No data
Doses / concentrations
- Remarks:
- Doses / Concentrations:
10.6 mg/m3
Basis:
other: concentration per P2O5
- No. of animals per sex per dose:
- NO data
- Control animals:
- not specified
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Remarks on result:
- not determinable
- Remarks:
- no NOAEL identified
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
The chronic inhalation of hydro-aerosol of phosphoric acid in a concentration of 10.6 mg/m3 per P2O5 resulted in the dysfunction of rats' liver (i.e. reduction of glycogen in liver and of albumin in blood serum), increased levels of inorganic phosphorus in blood and the increase in a relative weight of lungs, kidneys and spleen.
From morphological point of view, the animals developed the progressive bronchitis which resulted in the deformation of bronchi walls and the development of bronchiectasis. In addition, it was registered that there were dystrophic changes of hepatocytes in liver; epithelial degeneration of convoluted tubules in kidneys; and hyperemia and increased malpighian corpuscles in spleen.
Applicant's summary and conclusion
- Conclusions:
- The chronic inhalation of hydro-aerosol of phosphoric acid in a concentration of 10.6 mg/m3 per P2O5 resulted in the dysfunction of rats' liver (i.e. reduction of glycogen in liver and of albumin in blood serum), increased levels of inorganic phosphorus in blood and the increase in a relative weight of lungs, kidneys and spleen.
From morphological point of view, the animals developed the progressive bronchitis which resulted in the deformation of bronchi walls and the development of bronchiectasis. In addition, it was registered that there were dystrophic changes of hepatocytes in liver; epithelial degeneration of convoluted tubules in kidneys; and hyperemia and increased malpighian corpuscles in spleen.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
